Afficher la couverture 'A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021 | Mirand, Audrey' en grand format
/5

0 avis

A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021

Archive ouverte

Mirand, Audrey | Cohen, Robert | Bisseux, Maxime | Tomba, Stéphanie | Sellem, Fabienne Cahn | Gelbert, Nathalie | Béchet, Stéphane | Frandji, Bruno | Archimbaud, Christine | Brebion, Amélie | Chabrolles, Hélène | Regagnon, Christel | Levy, Corinne | Bailly, Jean-Luc | Henquell, Cécile

Edité par CCSD ; European Centre for Disease Prevention and Control -

International audience. We report a large-scale outbreak of hand, foot and mouth disease (HFMD) in France. As at 28 September 2021, 3,403 cases have been reported (47% higher than in 2018–19). We prospectively analysed 210 clinical samples; 190 (90.5%) were enterovirus-positive. Most children presented with atypical HFMD. Coxsackievirus (CV)A6 (49.5%; 94/190) was predominant; no enterovirus A71 was detected. Dermatological and neurological complications of HFMD justify prospective syndromic and virological surveillance for early detection of HFMD outbreaks and identification of associated types.

Suggestions

Du même auteur

Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing

Archive ouverte | Combes, Patricia | CCSD

International audience. Objectives: To describe Delta/Omicron SARS-CoV-2 variants co-infection detection and confirmation during the fifth wave of COVID-19 pandemics in France in 7 immunocompetent and epidemiologica...

Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers

Archive ouverte | Bonnet, Benjamin | CCSD

International audience. Clinical trials and real-world evidence on COVID-19 vaccines have shown their effectiveness against severe disease and death but the durability of protection remains unknown. We analysed the ...

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection

Archive ouverte | Bingula, Rea | CCSD

International audience. The third, "booster", vaccination increases the overall immune response against SARS-CoV-2 variants. However, after the initial peak at around 3 weeks post-vaccination, anti-spike antibody le...

Chargement des enrichissements...